On January 25, 2022, Metagenomi, a genetic medicines company with a versatile portfolio of next-generation gene editing tools, announced the completion of an up-sized and oversubscribed $175 million Series B financing. This brings the ​​total amount of funding for the company to $300 million. Proceeds from the financing will be used to advance Metagenomi’s lead in vivo and ex vivo gene editing therapeutic programs through preclinical development and into the clinic. This will include expansion of its manufacturing, automation and AI infrastructure, and further development of the company’s differentiated toolbox of next-generation gene editing systems. Wilson Sonsini Goodrich & Rosati advised Metagenomi on patent matters related to the transaction.

The Series B financing was led by PFM Health Sciences, Farallon Capital Management, and a leading global investment firm. Additional new investors include Eventide Asset Management, Deep Track Capital, Frazier Life Sciences, Pura Vida Investments, Irving Investors, Millennium Management, Surveyor Capital (a Citadel company), Marshall Wace, Novo Holdings A/S, and Bristol Myers Squibb. This financing round also included investment from strategic partner Moderna, as well as existing investors RA Capital Management, Leaps by Bayer, and Humboldt Fund, among others.

The Wilson Sonsini team that advised Metagenomi on patent matters related to the transaction included Ali Alemozafar, Michael Hostetler, Eric Grote, and Brandon Tavshanjian.

For more information, please see Metagenomi's press release.